Association of the angiotensinogen M235T and APO e gene polymorphisms in turkish type 2 diabetic patients with and without nephropathy

Renal Failure

Volumn 33, Issue 5, 2011, Pages 469-474

  Reis, Kadriye Altok ^a   Ebinç, Fatma Ayerden ^a   Koç, Eyüp ^a   Demirci, Hüseyin ^a   Erten, Yasemin ^a   Güz, Galip ^a   Derici, Ülver Boztepe ^a   Bali, Musa ^a   Sööylemezǒlu, Ǒuz ^a   Arinsoy, Turgay ^a   Sindel, Şükrü ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

angiotensinogen; APO E; Diabetic nephropathy; gene polymorphism

Indexed keywords

ANGIOTENSINOGEN; APOLIPOPROTEIN E;

ADULT; ALLELE; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

AGED; ALLELES; AMINO ACID SUBSTITUTION; ANGIOTENSINOGEN; APOLIPOPROTEINS E; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; TURKEY;

EID: 79956280493     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2011.568133     Document Type: Article

References (55)

1. Ha SK, Park HS, Kim KW, et al. Association between apolipoprotein E polymorphism and macroalbuminuria in patients with non-insulin dependent diabetes mellitus. Nephrol Dial Transplant. 1999;14(9):2144-2149. (Pubitemid 29403403)
2. Parving HH. Renoprotection in diabetes: Genetic and nongenetic risk factors and treatment. Diabetologia. 1998; 41(7):745-759.
3. Schmidt S, Ritz E. Genetics of the renin-angiotensin system and renal disease: A progress report. Curr Opin Nephrol Hypertens. 1997;6(2):146-151. (Pubitemid 27211776)
4. Vijay V, Snehalatha C, Shina K, Lalitha S, Ramachandran A. Familial aggregation of diabetic kidney disease in type 2 diabetes in south India. Diabetes Res Clin Pract. 1999;43(3):167-171. (Pubitemid 29202126)
5. Ayodele OE, Alebiosu CO, Salako BL. Diabetic nephropathy - A review of the natural history, burden, risk factors and treatment. J Natl Med Assoc. 2004;96(11):1445-1454. (Pubitemid 39482990)
6. Leiva E, Mujica V, Elematore I, et al. Relationship between apolipoprotein E polymorphism and nephropathy in type-2 diabetic patients. Diabetes Res Clin Pract. 2007;78(2):196-201. (Pubitemid 47451528)
7. Chowdhury TA, Dyer PH, Sudhesh K, Barnett AH, Bain SC. Genetic determinants of diabetic nephropathy. Clin Sci. 1999;96:221-230. (Pubitemid 29129172)
8. Burden AC, McNally PG, Feehally J, Walls J. Increased incidence of and-stage renal failure secondary to diabetes mellitus in Asian ethnic groups in the United Kingdom. Diabet Med. 1992;9:641-645.
9. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM. Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med. 1989;321:1074-1079. (Pubitemid 19256660)
10. Haffner SM, Mitchell BD, Pugh JA, et al. Proteinuria in Mexican- Americans and non-Hispanic whites with NIDDM. Diabetes Care. 1986;12:530-536.
11. Maeda S, Osawa N, Hayashi T, Tsukada S, Kobayashi M, Kikkawa R. Genetic variations associated with diabetic nephropathy and type II diabetes in a Japanese population. Kidney Int Suppl. 2007;106:S43.
12. Freedman BI, Bostrom M, Daeihagh P, Bowden DW. Genetic factors in diabetic nephropathy. Clin J Am Soc Nephrol. 2007;2(6):1306-1316. Epub 2007 October 17.
13. Guan J, Zhao HL, Baum L, et al. Apolipoprotein E polymorphism and expression in type 2 diabetic patients with nephropathy: Clinicopathological correlation. Nephrol Dial Transplant. 2009;24(6):1889-1895. Epub 2009 February 14.
14. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH. Genetic variation in the Renin-Angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003;14(11):2843-2850. (Pubitemid 37305647)
15. Liu L, Xiang K, Zheng T, Zhang R, Li M, Li J. Co-inheritance of specific genotypes of HSPG and ApoE gene increases risk of type 2 diabetic nephropathy. Mol Cell Biochem. 2003;254(1-2):353-358. (Pubitemid 37483772)
16. Burns KD. Angiotensin II and its receptors in the diabetic kidney. Am J Kidney Dis. 2000;36(3):449-467.
17. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev. 2000;52(1):11-34. (Pubitemid 30127593)
18. Ahluwalia TS, Ahuja M, Rai TS, et al. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol. 2009;28(3):141-150.
19. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell. 1992;71(1):169-180.
20. Jeunemaitre X, Inoue I, Williams C, et al. Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet. 1997;60(6):1448-1460. (Pubitemid 27258077)
21. Hopkins PN, Lifton RP, Hollenberg NK, et al. Blunted renal vascular response to angiotensin II is associated with a common variant of the angiotensinogen gene and obesity. J Hypertens. 1996;14(2):199-207. (Pubitemid 26121862)
22. Young RP, Chan JC, Critchley JA, Poon E, Nicholls G, Cockram CS. Angiotensinogen T235 and ACE insertion/deletion polymorphisms associated with albuminuria in Chinese type 2 diabetic patients. Diabetes Care. 1998;21(3):431-437. (Pubitemid 28101081)
23. Wang J, Zhu X, Yang L, Liu Y, Zhou W, Li H. Relationship between angiotensinogen gene M235T variant with diabetic nephropathy in Chinese NIDDM. Chin Med J (Engl). 1999;112(9):797-800.
24. Wu S, Xiang K, Zheng T, et al. Relationship between the renin-angiotensin system genes and diabetic nephropathy in the Chinese. Chin Med J (Engl). 2000;113(5):437-441.
25. Eroglu Z, Cetinkalp S, Erdogan M, et al. Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphisms in Turkish type 2 diabetic patients with and without nephropathy. J Diabetes Complications. 2008;22(3):186-190. Epub 2008 April 16. (Pubitemid 351539058)
26. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352(9123):213-219. (Pubitemid 28327814)
27. Moorhead JF, Chan MK, El-Nahas M, et al. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet. 1982;2(8311):1309-1311. (Pubitemid 13240921)
28. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science. 1988;240: 622-630.
29. Araki S, Koya D, Makiishi T, et al. APOE polymorphism and the progression of diabetic nephropathy in Japanese subjects with type 2 diabetes: Results of a prospective observational follow- up study. Diabetes Care. 2003;26(8):2416- 2420. (Pubitemid 36993336)
30. Eto M, Saito M, Okada M, et al. E genetic polymorphism, remnant lipoproteins, and nephropathy in type 2 diabetic patients. Am J Kidney Dis. 2002;40(2):243-251. (Pubitemid 34827641)
31. Ilhan N, Kahraman N, Seçkin D, Ilhan N, Colak R. Apo E gene polymorphism on development of diabetic nephropathy. Cell Biochem Funct. 2007;25(5):527-532. (Pubitemid 47436093)
32. Doria A, Warram JH, Krolewski AS. Genetic susceptibility to nephropathy in insulin-dependent diabetes: From epidemiology to molecular genetics. Diabetes Metab Rev. 1995;11(4):287-314. (Pubitemid 26045061)
33. Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia. 1990;33(8):470-476. (Pubitemid 20254869)
34. Lindholm LH, Ibsen H, Dahlöf B, et al. LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002 23;359(9311):1004-1010. (Pubitemid 34286537)
35. Freire MB, Ji L, Onuma T, Orban T, Warram JH, Krolewski AS. Gender-specific association of M235T polymorphism in angiotensinogen gene and diabetic nephropathy in NIDDM. Hypertension. 1998;31(4):896-899. (Pubitemid 28185564)
36. Campbell DJ, Lawrence AC, Towrie A, Kladis A, Valentijn AJ. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension. 1991;18(6):763-773.
37. Fogarty DG, Harron JC, Hughes AE, Nevin NC, Doherty CC, Maxwell AP. A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM. Diabetes. 1996;45(9):1204-1208. (Pubitemid 26296320)
38. Liberopoulos EN, Miltiadous GA, Cariolou M, Tselepis AD, Siamopoulos KC, Elisaf MS. The influence of serum apolipoprotein E concentration and polymorphism on serum lipid parameters in hemodialysis patients. Am J Kidney Dis. 2004;44(2):300-308. (Pubitemid 38962559)
39. Rippin JD, Patel A, Bain SC. Genetics of diabetic nephropathy. Best Pract Res Clin Endocrinol Metab. 2001;15(3):345-358. (Pubitemid 32916266)
40. Ji ZS, Pitas RE, Mahley RW. Differential cellular accumulation/ retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. Apolipoproteins E3 and E2 greater than E4. J Biol Chem. 1998;273(22):13452- 13460. (Pubitemid 28268384)
41. Dong LM, Parkin S, Trakhanov SD, et al. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia. Nat Struct Biol. 1996;3(8):718-722. (Pubitemid 26260063)
42. Joss N, Jardine A, Gaffney D, Boulton-Jones JM. Influence of apolipoprotein E genotype on progression of diabetic nephropathy. Nephron Exp Nephrol. 2005;101(4):e127-e133. Epub 2005 August 19.
43. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem. 2001;276(52):49142-49147. Epub 2001 September 28.
44. Chowdhury TA, Dyer PH, Kumar S, et al. Association of apolipoprotein epsilon2 allele with diabetic nephropathy in Caucasian subjects with IDDM. Diabetes. 1998;47(2):278-280.
45. Kimura H, Suzuki Y, Gejyo F, et al. Apolipoprotein E4 reduces risk of diabetic nephropathy in patients with NIDDM. Am J Kidney Dis. 1998;31(4):666-673. (Pubitemid 28158008)
46. Onuma T, Laffel LM, Angelico MC, Krolewski AS. Apolipoprotein E genotypes and risk of diabetic nephropathy. J Am Soc Nephrol. 1996;7(7):1075-1078. (Pubitemid 27465972)
47. Boizel R, Benhamou PY, Corticelli P, Valenti K, Bosson JL, Apo HS. E polymorphism and albuminuria in diabetes mellitus: A role for LDL in the development of nephropathy in NIDDM? Nephrol Dial Transplant. 1998;13(1):72-75. (Pubitemid 28033582)
48. Kwon MK, Rhee SY, Chon S, et al. Association between apolipoprotein E genetic polymorphism and the development of diabetic nephropathy in type 2 diabetic patients. Diabetes Res Clin Pract. 2007;77(Suppl. 1):S228-S232. (Pubitemid 47212581)
49. Saito M, Eto M, Makino I. Triglyceride-rich lipoproteins from apolipoprotein E3/2 subjects with hypertriglyceridemia enhance cholesteryl ester synthesis in human macrophages. Atherosclerosis. 1997;129(1):73-77. (Pubitemid 27104253)
50. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: Insights from experimental data and clinical studies. Diabetes Metab. 2000;26(4):254-264.
51. Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl. 1999;71:S51-S53. (Pubitemid 29304813)
52. Saraswathi V, Hasty AH. The role of lipolysis in mediating the proinflammatory effects of very low density lipoproteins in mouse peritoneal macrophages. J Lipid Res. 2006;47(7):1406-1415. (Pubitemid 44079894)
53. Cooper ME. Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet. 1998;352(9123):213-219. (Pubitemid 28327814)
54. Tenger C, Zhou X. Apolipoprotein E modulates immune activation by acting on the antigen-presenting cell. Immunology. 2003;109(3):392-397. (Pubitemid 36783265)
55. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem. 2001;276(52):49142-49147.